Quanta Dialysis Technologies

Quanta Dialysis Technologies manufactures the Quanta Dialysis System, an award-winning hemodialysis platform designed to deliver kidney replacement therapy across multiple care settings—acute care (ICU), post-acute facilities (LTAC, skilled nursing/rehabilitation), in-center chronic dialysis, and home-based self-care. The system is FDA-cleared (510(k) K222067 and K242269) to support multiple modalities—Intermittent Hemodialysis (IHD), Sustained Low-Efficiency Dialysis (SLED), Continuous Renal Replacement Therapy (CRRT), and Prolonged Intermittent Renal Replacement Therapy (PIRRT)—from a single platform without the need for dialysate bags or daily rinses. Key clinical features include a wide blood flow range (Qd 50–500 mL/min), precision electrolyte control (sodium and potassium), and an intuitive touchscreen interface enabling rapid staff training (4.5–6 hours). The system weighs 71 lbs and features a compact, modular design suitable for resource-constrained or transitional care environments. Maintenance requires only once-weekly hot rinses, with no harsh chemical disinfections. The company received the prestigious Royal Academy of Engineering MacRobert Award in 2022 for on-demand dialysate technology. Home hemodialysis clearance (2024) permits patient use with a trained care partner, with >95% success rate in human factors testing and 84% patient retention post-trial. Blood tube sets are single-use, disposable accessories. Quanta serves hospitals, dialysis centers, long-term acute care facilities, skilled nursing facilities, rehabilitation centers, and home dialysis patients across North America and Europe.